1Romano G,Michell P,Pacilio C,el al.Latest developments in gene trans-fer technology:achievements,perspec-tives,and controversies over therape-utic applications.Stem Cells.2000;18(1):19-39.
2Seregin SS,Amalfitano A.Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.Expert Opin Biol Ther.2009;9(12):1521-1531.
3Elson DA,Thurston G,Huang LE,et al.Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1 alpha.Genes Dev.2001;15(19):2520-2532.
5Khan TA,Sellke FW,Laham RJ.Gene therapy progress and prospects:therapeutic angiogenesis for limb and myocardial ischemia.Gene Ther.2003; 10(4):285-291.
6Giaccia A,Siim BG,Johnson RS.HIF-1 as a target for drug development.Nat Rev Drug Discov.2003;2(10):803-811.
7Qutub AA,Popel AS.Reactive oxygen species regulate hypoxia-inducible factor 1 alpha differentially in cancer and ischemia.Mol Cell Biol.2008;28(16):5106-5119.
8Semenza GL.Evaluation of HIF-1 inhibitors as anticancer agents.Drug Discov Today.2007; 12(19-20):853-859.
9Cheng LF,Yang XM.Relationship between hypoxia-inducible factor-1 and tumor.Shiyong Zhongliuxue Zazhi.2007;21(4):370-373.
10Lim W,Cho J,Kwon HY,et al.Hypoxia-inducible factor 1 alpha activates and is inhibited by unoccupied estrogen receptor beta.FEBS Lett.2009;583(8):1314-1318.
